Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study to Evaluate the Safety and Tolerability of AMG 655 in Combination With Bortezomib or Vorinostat in Subjects With Relapsed or Refractory Lymphoma

NCT00791011 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00791011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00791011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study to Evaluate the Safety and Tolerability of AMG 655 in Combination With Bortezomib or Vorinostat in Subjects With Relapsed or Refractory Lymphoma
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
February 29, 2008
Completion date
August 31, 2011
Enrollment
33 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large cell lymphoma, hodgkin's lymphoma, low grade lymphoma, lymphoma, mantle cell lymphoma, non-hodgkin's lymphoma